Literature DB >> 19162266

Comparability of methods for LDL subfraction determination: A systematic review.

Mei Chung1, Alice H Lichtenstein, Stanley Ip, Joseph Lau, Ethan M Balk.   

Abstract

Identifying and aggressively treating individuals at elevated risk of developing cardiovascular disease (CVD) is critical to optimizing health outcomes. The CVD risk factors defined by the National Cholesterol Education Program do not fully predict individuals at high risk of developing CVD. Validation of potential methodologies against a reference method is essential to the adoption of a potential new risk factor to improve risk prediction. Low-density lipoprotein (LDL) subfraction has been advanced as a potential additional CVD risk factor. Currently, there is no reference method for determining LDL subfractions or standardizing the different methods used to measure LDL subfractions. We conducted a systematic review to identify reports comparing two or more methods of measuring LDL subfractions. Nine articles were identified that separated and quantified LDL subfractions by at least two methods. Comparative data were available for nuclear magnetic resonance vs. gel electrophoresis (GE), LipoPrint vs. other GE methods, ultracentrifugation vs. GE, and high performance gel filtration chromatography vs. GE. We found a wide range of agreement (from 7 to 94% concordance for classifying LDL patterns) among methods for LDL subfraction determinations. Different criteria and definitions were used among the articles to classify individuals with respect to CVD risk. No study used CVD or other clinical outcomes as an outcome measure. In summary, the currently available literature does not provide adequate data about comparability in terms of test performance to choose one or another method to serve as a standard nor are data on comparability in terms of predicting CVD outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19162266     DOI: 10.1016/j.atherosclerosis.2008.12.011

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

2.  Lipoprotein subfractions and particle size in end-stage renal disease.

Authors:  Peter A McCullough; Fawaz Al-Ejel; Robert C Maynard
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

3.  Separation of the principal HDL subclasses by iodixanol ultracentrifugation.

Authors:  Nicola L Harman; Bruce A Griffin; Ian G Davies
Journal:  J Lipid Res       Date:  2013-05-20       Impact factor: 5.922

Review 4.  The role of advanced lipid testing in the prediction of cardiovascular disease.

Authors:  Alvin Chandra; Anand Rohatgi
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113

Review 5.  Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.

Authors:  Stanley Ip; Alice H Lichtenstein; Mei Chung; Joseph Lau; Ethan M Balk
Journal:  Ann Intern Med       Date:  2009-04-07       Impact factor: 25.391

6.  Small dense LDL particles--a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study.

Authors:  Anne P Toft-Petersen; Hans H Tilsted; Jens Aarøe; Klaus Rasmussen; Thorkil Christensen; Bruce A Griffin; Inge V Aardestrup; Annette Andreasen; Erik B Schmidt
Journal:  Lipids Health Dis       Date:  2011-01-25       Impact factor: 3.876

Review 7.  Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.

Authors:  Ekaterina A Ivanova; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Oxid Med Cell Longev       Date:  2017-05-07       Impact factor: 6.543

Review 8.  Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?

Authors:  Marília Izar Helfenstein Fonseca; Isis Tande da Silva; Sandra Roberta G Ferreira
Journal:  Diabetol Metab Syndr       Date:  2017-04-07       Impact factor: 3.320

9.  Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial.

Authors:  Krista A Varady; Surabhi Bhutani; Monica C Klempel; Cynthia M Kroeger; John F Trepanowski; Jacob M Haus; Kristin K Hoddy; Yolian Calvo
Journal:  Nutr J       Date:  2013-11-12       Impact factor: 3.271

10.  Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.

Authors:  Takahiro Sawada; Hideo Tsubata; Naoko Hashimoto; Michinori Takabe; Taishi Miyata; Kosuke Aoki; Soichiro Yamashita; Shogo Oishi; Tsuyoshi Osue; Kiminobu Yokoi; Yasue Tsukishiro; Tetsuari Onishi; Akira Shimane; Yasuyo Taniguchi; Yoshinori Yasaka; Takeshi Ohara; Hiroya Kawai; Mitsuhiro Yokoyama
Journal:  Cardiovasc Diabetol       Date:  2016-08-26       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.